UCapital NewsBusiness Super App · news connected to data, companies, people and deals
IT
VoicesWire
LIVE
BREAKING LIVE

The news moving markets, right now

From international newswires in real time. For every story the News Impact AI agent estimates the market impact and flags the assets to watch, with the story’s impact on each: positive, negative or neutral.

STORIES TODAY
176
via seekingalpha.comBusiness & Companies

Summit Therapeutics reports survival benefit for ivonescimab in biliary tract cancer trial

FROM THE WIRE · SEEKINGALPHA.COM

[Male doctor visiting female cancer patient with care and compassion in hospital room. Oncology support medical consultation healthcare and hope. Doctor reporting medical test results to the patient] chanakon laorob Summit Therapeutics (SMMT…

Read at the source ↗
MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishThe positive phase 3 result for Summit and partner Akeso may affect expectations for the drug in oncology.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
  1. 01Summit Therapeutics reported that ivonescimab significantly extended survival in patients with advanced biliary tract cancer.
  2. 02The phase 3 HARMONi-GI1 study was conducted in China by partner Akeso.
  3. 03Median overall survival was 14.9 months versus 12.1 months with Imfinzi plus chemotherapy.
  4. 04The results come from a late-stage clinical trial.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Summit Therapeutics Inc.SMMTStock15.47 USDMarket closedtoday -0.51%Positive AstraZeneca PLCAZNStock171.49 USDMarket closedtoday -0.63%Negative Merck & Co., Inc.MRKStock145.27 USDMarket closedtoday -1.34%Neutral
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets

ALL BREAKING TODAY

Breaking live stories come from third-party newswires via feed; headline and summary belong to the stated source. Impact analysis: UCapital AI · News Impact.

UCapital News is the news section of UCapital24 S.p.A. All content is for information purposes only and does not constitute financial advice, a recommendation or a solicitation to invest. Even where terms such as “buy”, “sell”, “bullish” or “bearish”, or asset impact signals, appear, they only indicate the possible effect of a news item on the markets and are not an invitation to buy or sell financial instruments. News is analysed with UCapital AI and may also be published via API feeds from third-party providers, to give our users a continuous flow of news. UCapital24 S.p.A. accepts no liability of any kind for decisions made on the basis of this content. Wire releases are published by companies and are not verified by the newsroom.

AI use policy. UCapital AI supports the newsroom with news analysis, summaries, market reactions, translations and the generation of cards and charts. AI-generated or AI-assisted content is labelled in the byline (AI Desk, a named AI profile marked «AI», or joint byline) and is reviewed by editors before publication. News received via API feeds from third-party providers is attributed to the original source. AI can make mistakes: report any inaccuracies to the newsroom. Users’ personal data is not used to train the models.